Bristol-Myers Squibb
BMY
2,543 hedge funds and large institutions have $98.1B invested in Bristol-Myers Squibb in 2026 Q1 according to their latest regulatory filings, with 271 funds opening new positions, 1,066 increasing their positions, 878 reducing their positions, and 151 closing their positions.
79% more first-time investments, than exits
New positions opened: 271 | Existing positions closed: 151
21% more repeat investments, than reductions
Existing positions increased: 1,066 | Existing positions reduced: 878
16% more funds holding in top 10
Funds holding in top 10: 31 → 36 (+5)
11% more capital invested
Capital invested by funds: $88.5B → $98.1B (+$9.6B)
3% more funds holding
Funds holding: 2,461 → 2,543 (+82)
4% less call options, than puts
Call options by funds: $1.48B | Put options by funds: $1.54B
1.3% less ownership
Funds ownership: 80.63% → 79.33% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.02B |
| 2 |
JP Morgan Chase
New York
|
+$997M |
| 3 |
Two Sigma Investments
New York
|
+$401M |
| 4 |
SG Americas Securities
New York
|
+$366M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$345M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$732M |
| 2 |
Charles Schwab
San Francisco,
California
|
-$595M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$485M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$417M |
| 5 |
BlackRock
New York
|
-$300M |
BMY Hedge Fund Activity: Q1 2026 in Review
2,543 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q1 2026, worth a combined $98.1B — up 11% from $88.5B a quarter earlier.
Buyers outnumbered sellers: 271 funds opened new BMY positions and 151 closed out — a net gain of 120 holders — while 1,066 added to existing stakes and 878 trimmed.
The largest buyer was Bank of America, adding an estimated $1.02B. The largest seller was Capital International Investors, cutting an estimated $732M.
- 2,543 institutional investors held Bristol-Myers Squibb (BMY) as of Q1 2026, up from 2,461 in Q4 2025.
- Funds reported $98.1B of Bristol-Myers Squibb stock for Q1 2026, up 11% quarter-over-quarter.
- 271 funds opened new Bristol-Myers Squibb positions in Q1 2026 and 151 closed out, a net change of +120 holders.
- The largest Bristol-Myers Squibb buyer in Q1 2026 was Bank of America, an estimated $1.02B added.
- The largest Bristol-Myers Squibb seller in Q1 2026 was Capital International Investors, an estimated $732M sold.
Based on aggregated 13F filings for Q1 2026.